First-Trimester Inhaled Steroid Continuation Shows No Excess Pregnancy Risk

This nationwide cohort adds reassuring maternal-neonatal safety data supporting continuation of inhaled corticosteroids in early pregnancy, informing counseling of asthmatic patients of reproductive age.

inhaled corticosteroidsICSbudesonidefluticasonebeclomethasoneasthmapregnancyfirst trimesterpharmacoepidemiologycohort studycongenital malformationpreterm birthmaternal-fetal medicineGINA Pediatric Pharmacy

Background Information

Continue ICS during pregnancy to safely control asthma.

Asthma control during pregnancy is crucial for preventing complications, and understanding the impact of inhaled corticosteroids (ICS) can guide clinical practice. ICS continuation in the first trimester showed no significant increase in risks for maternal or neonatal outcomes such as gestational diabetes or congenital malformations. The study supports guidelines recommending continued ICS use during pregnancy, emphasizing the importance of maintaining asthma control without added risk. ICS use in early pregnancy does not increase risk and should be continued to maintain asthma control.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Suh B, Cho Y, Choi EY, Lee H, Kang HR, Kim H, Man KKC, Shin JY, Noh Y

Citation: Suh B, Cho Y, Choi EY, et al. Inhaled Corticosteroids Continuation in the First Trimester and Pregnancy Outcomes in Women With Asthma. JAMA network open. 2026;9(8):e2630781. doi:10.1001/jamanetworkopen.2026.30781

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →